# Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

> **NCT03361800** · EARLY_PHASE1 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Breast Cancer
- Invasive Breast Cancer
- ER-Negative PR-Negative HER2-Negative Breast Cancer

## Interventions

- **DRUG:** Entinostat

## Key facts

- **NCT ID:** NCT03361800
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-28
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-10-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Funding withdrawn.
- **Last updated:** 2024-03-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361800, "Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03361800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*